Institut National De La Sante Et De La Recherche Medicale

Institut National De La Recherche Agronomique

Assistance Publique-hopitaux De Paris

Institut National De La Recherche Agronomique (inra)

Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement

Sorbonne Université

Université Pierre Et Marie Curie (Paris 6)

Ecole Nationale Veterinaire D'alfort

Centre National De La Recherche Scientifique

Ares Trading S.a.

Compagnie Gervais Danone

Université Paris Diderot-Paris 7

Assistance Publique - Hopitaux De Paris (aphp)

Institut Pasteur

Inserm (institut National De La Sante Et De La Recherche Medicale)

Philippe Langella

Harry Sokol

Luis G Bermudez-Humaran

Rebeca Martin Rosique

Luis Bermudez Humaran

Muriel Thomas

Marie-Laure Michel

Bruno Michel Lamas

Mathias Lavie-Richard

Florian Chain

Jean-Marc Chatel

Bruno Polack

Yolande Chvatchko

Tamara Smokvina

Johan Van Hylckama Vlieg

Marie-Agnes Travers

Philippe Grellier

Isabelle Florent

Thibault Allain

Vassilia Theodorou

Nathalie Vergnolle

Germain Trugnan

Laurence Goffin

Marie-Anne Maubert

Sylvie Miquel

Frédéric Carvalho

Henri Duboc

Jane Mea Natividad

Maria Elena Sanchez-Pardo

Edgar Torres Maravilla

Aude Remot-Brizion

Jean-Michel Sallenave

Simone Favre-Zimmerli

Camille Aubry

Luis Bermudez-Humaran

Benedicte Pigneur-Arnaud

Elodie Quevrain

Philippe Seksik

Christophe Michon

Patrick Veiga

Bruno Lamas

Mathias Richard

Jane Natividad

Marie-Agnès Travers

The present invention relates to a bacterial strain of thespecies selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

strains for treating and preventing gastrointestinal pain

The present invention relates to the preventive or curative treatment of metabolic syndrome and the associated disorders with AhR agonist or microorganism producing AhR agonist.

Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders

The present disclosure relates to a new probiotic strain of, isolated from pulque and exhibiting anti-cancer properties, as well as to compositions which contain said strain.

Probiotic strain of

The present invention relates to a composition comprising a givenstrain and a givenstrain wherein the ratio of the givenstrain to the givenstrain (LR&#x3b1;:LP&#x3b1;) is higher or equal to 8:1 and to methods thereof.

Probiotic composition comprisingandand methods thereof

The invention relates to a novel bacterial strain deposited with the CNCM under number 1-4969. This strain has properties that are useful in the treatment of respiratory disorders. The invention also relates to compositions and uses of said strain.

Bacterial strain as agents for preventing and/or treating respiratory disorders

The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH)enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

Compositions for the inhibition of

A method for preventing or treating an inflammatory disease, such as inflammatory bowel disease and Crohn disease, is presented. The method includes administering to a patient a polypeptide having the amino acid sequence of SEQ ID NO: 1, a conservative derivative or a fragment thereof, a nucleic acid sequence encoding said polypeptide, a vector comprising said nucleic acid sequence or a host cell that has been transfected, infected or transformed by said nucleic acid sequence and/or by said vector.

Anti-inflammatory peptides and methods for treating inflammatory diseases

The invention relates to a bacterial strain of speciesdeposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.

strain CNCM 1-4573 for the treatment and prevention of gastrointestinal inflammation

The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.

Pharmaceutical compositions for preventing or treating inflammatory bowel diseases

The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

[object Object]

The present invention relates to recombinantbacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.

Lactococcus lactis producing TSLP or IL-25 and their uses as probiotics and therapeutics

The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.

Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)

Growing community of inventors

Velizy, France

Philippe Langella